BDA-366
10mM in DMSO
- Product Code: 142749
CAS:
1909226-00-1
| Molecular Weight: | 423.5 g./mol | Molecular Formula: | C₂₄H₂₉N₃O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
BDA-366 is a selective antagonist of the liver X receptor (LXR), specifically targeting LXRβ. It has been investigated for its potential in modulating lipid metabolism and inflammation, making it a candidate for research in metabolic disorders such as atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Unlike full LXR agonists, which can increase triglyceride levels, BDA-366 offers a more favorable profile by inhibiting specific LXR-mediated pathways without promoting lipogenesis. This property makes it valuable in preclinical studies focused on cardiovascular health and metabolic syndrome. Additionally, BDA-366 has shown promise in cancer research, particularly in leukemia and prostate cancer models, where LXR signaling plays a role in cell proliferation and survival. Its ability to induce apoptosis in cancer cells without activating lipogenic genes highlights its therapeutic potential as a targeted agent in oncology.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,480.00 |
+
-
|
BDA-366
BDA-366 is a selective antagonist of the liver X receptor (LXR), specifically targeting LXRβ. It has been investigated for its potential in modulating lipid metabolism and inflammation, making it a candidate for research in metabolic disorders such as atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Unlike full LXR agonists, which can increase triglyceride levels, BDA-366 offers a more favorable profile by inhibiting specific LXR-mediated pathways without promoting lipogenesis. This property makes it valuable in preclinical studies focused on cardiovascular health and metabolic syndrome. Additionally, BDA-366 has shown promise in cancer research, particularly in leukemia and prostate cancer models, where LXR signaling plays a role in cell proliferation and survival. Its ability to induce apoptosis in cancer cells without activating lipogenic genes highlights its therapeutic potential as a targeted agent in oncology.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :